Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ia bukan cadangan pelaburan.
Perihal
Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy.
Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa Boerse Muenchen, saham Cassiopea S.p.A. didagangkan di bawah simbol CSP.MU.
Berapa ramai pekerja yang dimiliki oleh Cassiopea S.p.A.?▼
Sehingga 2 November 2026, syarikat mempunyai 11 pekerja.
Cassiopea S.p.A. terletak dalam sektor apa?▼
Cassiopea S.p.A. beroperasi dalam sektor Kesihatan & Kesejahteraan.
Bilakah Cassiopea S.p.A. menyiapkan split saham?▼
Cassiopea S.p.A. tidak mempunyai sebarang split baru-baru ini.
Di manakah ibu pejabat Cassiopea S.p.A.?▼
Ibu pejabat Cassiopea S.p.A. terletak di Lainate, Jerman.